We are developing a cutting-edge device platform to scale global manufacturing capacity, enabling cost-effective and safe cell therapies for all patients.

85%

complete remission in r/r ALL patients
after a cell therapy treatment

44%

still cancer free, four years after a single infusion of a cell therapy

<1%

of all blood cancer patients receive
a cell therapy

320K

price in EUR of a cell therapy
Kymriah, Germany 2020

Automation

Industrial automation increases product quality and scalability

Integration

Integrated process and quality control facilitates real-time process information

Miniaturization

Silicon and microfluidic structures enable processing on cellular level

Modularity

Functional modules allow individual process designs and conceptional flexibility